Worksite Tobacco Prevention: A Randomized, Controlled Trial of Adoption, Dissemination Strategies, and Aggregated Health-Related Outcomes across Companies
Table 2
Longitudinal changes with regard to worksite TP and health-related outcomes aggregated at company level (Wilcoxon tests).
Decrease
No change
Increase
Worksite TP1
Restrictiveness of smoking policy
2
3
9.4%
68.5%
22.1%
809
−5.941
<.001
−0.21
Number of individual support measures
0
0
9.1%
78.8%
12.1%
827
−1.609
.054
−0.06
SOC2 smoke-free policy
4
5
12.6%
54.8%
32.6%
786
−7.666
<.001
−0.27
SOC2 cessation courses
1
1
16.1%
65.6%
18.3%
771
−2.376
.009
−0.09
Health-related outcomes aggregated at company level
% smokers in the workforce3
2
2
17.7%
56.0%
26.3%
723
−3.254
<.001
−0.12
SHS4-related problems5
1
1
31.4%
49.0%
19.6%
816
−6.195
<.001
−0.22
Absenteeism due to illness5
2
2
27.0%
46.3%
26.8%
800
−0.790
.215
−0.03
Note. Median. Effect size. 1For scale coding, see Table 1. 2Stage of change. 31 = 0–20%, 5 = 80–100%. 4Environmental tobacco smoke. 5Answers were given on a five-point scale from 1 (“does not apply”) to 5 (“applies”).